The Institut Pasteur Shanghai (IPS) is the first international institute under the Chinese Academy of Sciences (CAS). Founded in 2004 by CAS, the Institut Pasteur and the Shanghai Municipal Government, IPS is an independent, nonprofit life sciences institute that works closely with Chinese authorities to address public health problems. IPS creates synergies between the Institut Pasteur and CAS networks, leveraging all the assets of Shanghai, one of Asia’s leading business and technology hubs. IPS is engaged in broad research related to infectious diseases, including research on HIV, viral hepatitis B and C, respiratory viruses and virus-induced cancers, etc. Together with its academic and industry partners, IPS’s goal is to develop diagnostic, vaccine and therapeutic products to meet the following challenges:
Ø Hand, Foot and Mouth Disease is on the rise in China. HFMD has affected more than 8 million children since 2008 and has caused over 2,500 deaths due to severe neurological and cardiovascular complications.
Ø HIV/AIDS and related tumors are the leading cause of death from infectious diseases in China. A vaccine is urgently needed.
Ø Acute Respiratory Infections (ARI, such as influenza, SARS, etc.) cause significant morbidity and mortality worldwide. Viruses from five different families cause ARI. Monitoring, novel therapies and vaccines targeting these viruses are needed to prevent future epidemics and pandemics.
Ø Viral hepatitis caused by hepatitis B and C viruses affects 140 million chronic carriers in China and leads to cirrhosis and cancer of the liver in millions of patients.
Talent Recruitment and Education
Thanks to its mission of research oriented to public health and education, IPS has been able to attract 23 unit heads from around the world through selective recruitment of high-level scientists conducting the most ambitious and innovative basic scientific research. Some were selected through the Thousand Talents global recruitment program sponsored by the Chinese government.
IPS trains young scientists in the field of biomedicine, taking full advantage of the expertise and resources offered by CAS and the International Network of Pasteur Institutes. Since it opened in 2005, IPS-CAS has offered educational programs at an international level in the fields of pathogens, vaccine, biosafety and inflammation, etc.
As of October 2013, IPS had 270 staff and students distributed among 23 research teams. This group includes 13 Ph.D. students, 82 M.S.-Ph.D. students and 27 M.S. students.
The scientific output of IPS-CAS has steadily increased since its founding. During the past several years, institute scientists have published 181 papers in peer-reviewed international journals. More importantly, many novel findings have led to patents that hold great potential for disease prevention or treatment.
Domestic and International Cooperation
IPS-CAS has set up strategic partnerships with domestic and international organizations to conduct basic research and develop products in key fields. Partners include major foundations such as the Li Ka-Shing Foundation, renowned institutes, and biotech and pharmaceutical companies. In the area of clinical research, IPS-CAS has collaborated with hospitals, the Chinese Academy of Medical Sciences and governmental agencies devoted to disease prevention and control.
IPS-CAS shares technology, resources and information with the 32 members of the Pasteur Institutes Network. IPS-CAS plays an important role among Pasteur Institutes in the Asia-Pacific region by participating in two of the network’s programs: the research-driven Response to Acute Respiratory Infections (RESPARI) program (see www.hku.hk/respari); and the Surveillance and Investigation of Epidemic Situations in Southeast Asia (SISEA) program, which is concerned with emerging diseases. Through these programs, network institutes share capacities, expertise and reagents related to emerging pathogens and collaborate in the areas of research, diagnosis, epidemiology and treatment. The network has its own international scientific advisory board and receives support from the international community, the French Ministry of Health and Solidarity, the French Agency for Development, and the Li Ka-Shing Foundation.
IPS-CAS and the Institut Pasteur of Cambodia collaborated to identify the human Enterovirus 71 (EV71) strain responsible for an outbreak of hand, foot and mouth disease in Cambodia in 2012. This achievement proves that IPS-CAS can play an important role in infectious disease research outside Mainland China. It also shows that IPS-CAS is a key China-based international organization in the field of infectious disease research and is committed to its mission of translating scientific excellence into public health benefits.
Contact: Fang Chen
Address: 320, Yueyang Road, Shanghai 200032
Tel: (86 21) 5492 3010
Fax: (86 21) 5492 3044
IPS Yueyang Campus & IPS Hefei Campus
miRNAs that target Pur-alpha modulate susceptibility of monocytes/DCs to HIV-1 infection. A) Pur-alpha displays inadequate expression in monocytes; B)The translation of Pur-alpha can be repressed by cellular microRNAs; C-F) The modulation of Pur-alpha by microRNAs regulates HIV-1 infection in monocytes (C and D) and DCs (E and F). G) Work model.
Histamine assists in HIV-1 modulation of MDDC effects on Treg cell differentiation. A) Scheme of the Treg cell differentiation assay. B) The Treg cell phenotype was detected by immunostaining with CD25 and Foxp3. C) Functional assay of Treg cell for suppressing T cell proliferation. D) Work model.